Valneva : Dans une bonne dynamique malgré un contexte défavorable
>Publication des résultats de VLA15 en phase 2 dans quelques jours - Nous attendons les résultats de phase 2 de VLA15 dans ces prochains jours. Pour rappel, le candidat vaccin a été pris sous licence de co développement avec Pfizer en avril dernier ce qui avait conduit notamment au relèvement de notre recommandation. Développé dans la maladie de Lyme, une maladie d’origine bactérienne qui se contracte via la morsure d’une tique, le candidat vaccin montrait des résulta...Valneva, together with its subsidiaries, is focused on vaccine development and antibody discovery. Co. generates revenue from both its marketed product, a vaccine for the prevention of Japanese encephalitis (IXIARO®/JESPECT®), commercial partnerships around a portfolio of product candidates and licensed technology platforms (EB66® cell line, VIVA,Screen antibody discovery technology, and the IC31® adjuvant) developed by Co. Related business activities include product research and development, regulatory and clinical activities, manufacturing of commercial product and advanced clinical product candidates, as well as administrative, corporate development, and marketing and sales activities.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.